- Home
- IGR vs TRVI Comparison
IGR vs TRVI Comparison
Compare IGR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- TRVI
- Stock Information
- Founded
- IGR 2004
- TRVI 2011
- Country
- IGR United States
- TRVI United States
- Employees
- IGR N/A
- TRVI N/A
- Industry
- IGR Finance Companies
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- TRVI Health Care
- Exchange
- IGR Nasdaq
- TRVI Nasdaq
- Market Cap
- IGR 752.8M
- TRVI 725.7M
- IPO Year
- IGR N/A
- TRVI 2019
- Fundamental
- Price
- IGR $4.92
- TRVI $7.42
- Analyst Decision
- IGR
- TRVI Strong Buy
- Analyst Count
- IGR 0
- TRVI 9
- Target Price
- IGR N/A
- TRVI $19.94
- AVG Volume (30 Days)
- IGR 747.7K
- TRVI 1.8M
- Earning Date
- IGR 01-01-0001
- TRVI 08-11-2025
- Dividend Yield
- IGR 13.93%
- TRVI N/A
- EPS Growth
- IGR N/A
- TRVI N/A
- EPS
- IGR N/A
- TRVI N/A
- Revenue
- IGR N/A
- TRVI N/A
- Revenue This Year
- IGR N/A
- TRVI N/A
- Revenue Next Year
- IGR N/A
- TRVI N/A
- P/E Ratio
- IGR N/A
- TRVI N/A
- Revenue Growth
- IGR N/A
- TRVI N/A
- 52 Week Low
- IGR $3.88
- TRVI $2.36
- 52 Week High
- IGR $5.70
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- IGR 35.64
- TRVI 62.05
- Support Level
- IGR $4.90
- TRVI $6.67
- Resistance Level
- IGR $5.07
- TRVI $8.11
- Average True Range (ATR)
- IGR 0.08
- TRVI 0.41
- MACD
- IGR -0.03
- TRVI 0.08
- Stochastic Oscillator
- IGR 11.84
- TRVI 63.00
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.